‘Electronic tongues’ may help diagnose early stage bladder cancer

By

New research presents a complex electronic device as a possible new, efficient, simple, and cost-effective way of detecting bladder cancer in its early stages and monitoring people living with bladder cancer.

In a quest to find a better way of diagnosing bladder cancer, Spain-based researchers from the Polytechnic University of Valencia (UPV), the La Fe Health Research Institute (IIS-La Fe) in Valencia, and the Centre for Biomedical Research in the fields of Bioengineering, Biomaterials and Nanomedicine in Madrid set out to develop a noninvasive method that harnessed the power of «taste-detecting» sensors. If you want to read more about this news, click here.

Posted in News, Science.
Share

Deja una respuesta

Tu dirección de correo electrónico no será publicada.

Related Posts

  •
    19 febrero, 2020

    ResMed ventilators recall is Class I

    FDA today designated a ResMed (NYSE:RMD) recall of certain Stellar non-invasive and invasive ventilators as Class I — the agency’s most serious level. The sound alarm on the ventilators may not work if the device has a failed electronic part, is stored without AC power for more than 36 hours, or powers on automatically when connected …

  •
    18 junio, 2019

    Using EEG data to diagnose Parkinson’s disease

    Researchers behind a new study believe that an EEG may be a more effective alternative. If you want to read more about this news click here  

  •
    21 febrero, 2020

    COFEPRIS Challenges 2020

    Since December 1st, 2018 a historical change in administration that consisted of a new president who is committed to Public Office cleansing of corrupt and unequal practices had a strong impact on the whole country course of operation. Many institutions were eliminated or were audited and restructured.  Cofepris was audited and analyzed for permanence or …

  •
    10 octubre, 2019

    Study: Abbott, Edwards may have mislabeled hundreds of patient deaths

    Abbott (NYSE:ABT) and Edwards Lifesciences (NYSE:EW) may have mislabeled patient deaths as injuries or device malfunctions in hundreds of FDA adverse event reports involving their transcatheter aortic or mitral valve replacement devices, according to a new study. The study by JAMA Internal Medicine editor Dr. Rita Redberg, former FDA unique device identification (UDI) external program manager Madris Tomes and others examined a total …